 Erythropoietin
"Erythropoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
| Descriptor ID |
D004921
|
| MeSH Number(s) |
D12.644.276.374.410.240.150 D12.776.395.240.150 D12.776.467.374.410.240.150 D23.529.374.410.240.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Erythropoietin".
Below are MeSH descriptors whose meaning is more specific than "Erythropoietin".
This graph shows the total number of publications written about "Erythropoietin" by people in this website by year, and whether "Erythropoietin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 1 | 0 | 1 | | 1989 | 0 | 1 | 1 | | 1991 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 0 | 2 | | 2007 | 6 | 0 | 6 | | 2008 | 5 | 4 | 9 | | 2009 | 5 | 0 | 5 | | 2010 | 4 | 1 | 5 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 1 | 2 | | 2013 | 2 | 0 | 2 | | 2015 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Erythropoietin" by people in Profiles.
-
Li X, Yu L, Shi X, Rao C, Zhou Y. Capillary isoelectric focusing with UV fluorescence imaging detection enables direct charge heterogeneity characterization of erythropoietin drug products. J Chromatogr A. 2021 Apr 26; 1643:462043.
-
Li X, Shi X, Qin X, Yu L, Zhou Y, Rao C. Interlaboratory method validation of imaged capillary isoelectric focusing methodology for analysis of recombinant human erythropoietin. Anal Methods. 2020 08 14; 12(30):3836-3843.
-
McMahon GM, Singh AK. Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019 11; 28(6):600-606.
-
Cowper B, Li X, Yu L, Zhou Y, Fan WH, Rao CM. Comprehensive glycan analysis of twelve recombinant human erythropoietin preparations from manufacturers in China and Japan. J Pharm Biomed Anal. 2018 May 10; 153:214-220.
-
Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, Claggett B, Liu J, Hartley LH, Finn P, Singh AK, Levey AS, Pfeffer MA, McMurray JJ, Solomon SD. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2015 Sep; 66(3):429-40.
-
Singh AK. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem. Semin Dial. 2013 Sep-Oct; 26(5):531-4.
-
McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.
-
Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46.
-
Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep; 60(3):390-401.
-
Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, Keithi-Reddy SR, McGill JB, McMurray JJ, Singh AK, Solomon SD, Uno H, Pfeffer MA. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|